Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Lansdowne Partners and Summit Therapeutics PLC (ADR) (SMMT)

Page 1 of 8

Summit Therapeutics PLC (ADR) (NASDAQ:SMMT): Alex Snow’s Lansdowne Partners filed an amended 13D.

You can check out Lansdowne Partners’ latest holdings and filings here.

Please follow Lansdowne Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Lansdowne Partners or update its stock holdings.

Alex Snow
Alex Snow
Lansdowne Partners

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Lansdowne Partners (UK) L 0 19,060,500 0 19,060,500 19,060,500 27.11%
Lansdowne Developed Markets Master Fund Limited 0 19,060,500 0 19,060,500 19,060,500 27.11%
Alex Snow
Alex Snow
Lansdowne Partners

Page 1 of 8 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13D/A
Amendment No. 2
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND
AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a)
Summit Therapeutics PLC
(Name of Issuer)
American Depositary Shares and Ordinary Shares, par value £0.01 per share
(Title of Class of Securities)
86627R102
(CUSIP Number)
Hugh Orange
c/o Lansdowne Partners (UK) LLP
15 Davies Street

London W1K 3AG

England

44-20-7290-5500
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
September 19, 2017
(Date of Event Which Requires Filing of this Statement)

If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D/A, and
is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box o.

Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for
other parties to whom copies are to be sent.

* The remainder
of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities and for any subsequent amendment containing information which would alter disclosures provided in the cover page.

The information
required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).

Follow Summit Therapeutics Plc
Trade () Now!
Page 1 of 8
Loading...